Harvard Apparatus Regenerative Technology Schedules Conference Call and Webcast for Q2 2023 Results
HOLLISTON, Mass., Aug. 9, 2023 /PRNewswire/ — Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“HRGN” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, including cancer, trauma and birth defects in the esophagus and other organs, today announced that it will release Q2 2023 financial results on August 14, 2023 and host a conference call and webcast on August 14, 2023 at 9:00 AM ET to discuss financial results and business updates for the second-quarter 2023. There will be an opportunity for Q&A.
Related news for (HRGN)
- Harvard Apparatus Regenerative Technology Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- Harvard Apparatus Regenerative Technology and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh Establish a Research Collaboration to Study the Repair and Regeneration of the Colon following Colectomy
- Harvard Apparatus Regenerative Technology and Renowned Professor/Physician Establish a Collaboration to Repair and Regenerate the Uterus
- Harvard Apparatus Regenerative Technology Reports Third Quarter 2023 Financial Results